Merck's Keytruda Keeps Nipping At Opdivo's Heels
In the US there are more new starts on Keytruda than any other immunotherapy, Merck says in first-quarter earnings report.
You may also be interested in...
Keytruda sales are soaring on first-line lung cancer use, but with many new filings and approvals, Merck tells its second-quarter earnings call it's just the beginning.
The recently launched Opdivo/Yervoy combination already has a leading position in first-line kidney cancer in the US – with a 30% share of new patients – but has been rejected in Europe.
Over two days, stakeholders will get a complete picture of the checkpoint inhibitor market as the four major immuno-oncology sponsors report second quarter sales and earnings.